CollPlant Biotechnologies

CollPlant Biotechnologies is a regenerative and aesthetic medicine company developing proprietary recombinant human Type I collagen (rhCollagen) produced in genetically engineered tobacco plants. Its portfolio spans a regenerative dermal filler (VergenixFG/STR), a 3D-bioprinted regenerative soft-tissue matrix, and a rhCollagen-based BioInk for 3D printing of tissues and organs. In June 2026 the company closed a $2.6M registered direct offering of ordinary shares and warrants with H.C. Wainwright as placement agent, with the press release flagging that the proceeds are intended to support ongoing R&D and the evaluation of strategic combinations.